Medpace (MEDP) Set to Post Earnings on Wednesday

Medpace (NASDAQ:MEDP) is expected to post its Q3 2026 results after the market closes on Wednesday, October 21st. Analysts expect Medpace to post earnings of $4.44 per share and revenue of $714.47 million for the quarter. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 22, 2026 at 9:00 AM ET.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%. The business’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.10 EPS. On average, analysts expect Medpace to post $17.54 EPS for the current fiscal year and $19.17 EPS for the next fiscal year.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $618.47 on Monday. The company has a 50 day simple moving average of $606.41 and a 200 day simple moving average of $532.57. The firm has a market cap of $17.26 billion, a PE ratio of 36.25, a price-to-earnings-growth ratio of 2.76 and a beta of 1.18. Medpace has a 1 year low of $373.00 and a 1 year high of $677.90.

Insider Buying and Selling

In other news, CEO August Troendle sold 21,966 shares of the stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $625.47, for a total value of $13,739,074.02. Following the completion of the sale, the chief executive officer directly owned 338,225 shares of the company’s stock, valued at $211,549,590.75. This represents a 6.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last three months, insiders sold 336,140 shares of company stock worth $208,008,328. Insiders own 20.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Mizuho lifted their target price on Medpace from $665.00 to $700.00 and gave the stock an “outperform” rating in a report on Wednesday, October 7th. Royal Bank Of Canada upped their price target on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Robert W. Baird increased their price target on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. Finally, Jefferies Financial Group restated a “hold” rating on shares of Medpace in a research report on Monday, September 14th. Three equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $607.73.

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace’s services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.